LVMUY-OTC 0 ACN-N -0.98 UNH-N -4.91 VALT-T 0.19 MART-T -0.15 VIDY-T 0.31 RPRX-Q 0.05
Daily Stock Opinions and Ratings
Stockchase Opinions

Hugh Cleland, CFA Resverlogix Corp. RVX-T COMMENT Dec 27, 2007

Have some compounds that are expected to boost HDL levels significantly. He usually has trouble with pure biotechs, which this one is. They consume vast amounts of cash. Prefers Neptune (NTB-X).
Hugh Cleland, CFAHugh Cleland, CFA
No
Unlock Rating
$15.420

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Resverlogix Corp.(RVX-T)

Jan 24, 2007
Treatment of Cardiovascular diseases. They’re on to a new way of looking at HDL treatment. Still pre-clinical. Prefers biotech that is at least in phase 2 trials. Too expensive.
Hugh Cleland, CFAHugh Cleland, CFA
No
Unlock Rating
$19.110

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Resverlogix Corp.(RVX-T)

Mar 26, 2007
Strong management. Have an interesting approach to HDL. Currently pre-clinical, so doesn't know if it works in humans or is safe.
Hugh Cleland, CFAHugh Cleland, CFA
No
Unlock Rating
$16.900

Stock price when the opinion was issued

biotechnology pharmaceutical
COMMENT

Resverlogix Corp.(RVX-T)

Aug 06, 2009
Only process that can reverse a cholesterol situation. A lot of big pharmas are looking at the name. Looks pretty attractive at this level. This is at phase 2 and he prefers buying after phase 3.
Peter HodsonPeter Hodson
No
Unlock Rating
$2.790

Stock price when the opinion was issued

biotechnology pharmaceutical
COMMENT

Resverlogix Corp.(RVX-T)

Nov 16, 2009
(Market Call Minute.)Reversing of bad cholesterol in clinical studies. A little early for him but has potential. Speculative.
Peter HodsonPeter Hodson
No
Unlock Rating
$2.580

Stock price when the opinion was issued

biotechnology pharmaceutical

Build our watch list

Sign in to track investments
you care about

Latest Buy Signals

AAXN-Q -2.24$684.59
RKLB-Q -2.59$20.51
ENB-T 0.51$64.3
CLF-N -0.15$7
PLTR-Q -1.85$117.3

Today's Top Picks

LVMUY-… 0$109.799
ACN-N -0.98$307.9
UNH-N -4.91$380.64
VALT-T 0.19$40.79
MART-T -0.15$22.75

Popular Articles

Latest Sell Signals

GOOG-Q -1.37$154.38
VRTX-Q -4.61$424.99
PLTR-Q -1.85$117.3
ZTS-N -2.42$159.27
ADBE-Q -0.71$383.28

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Michael Hakes - CFA, MBA

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brenda Vingiello, CIO, Sand Hill Global Advisors

Brenda Vingiello, CIO, Sand Hill Global Advisors

Sand Hill Global Advisors

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica